GILEAD SCIENCES INC

Explore how Gilead’s Kite sub‑unit’s new bispecific CAR‑T candidates and Yescarta data could reshape oncology reimbursement, margins and investor outlook.

Gilead’s Kite reports breakthrough CAR‑T data for relapsed/refractory large B‑cell lymphoma: Yescarta shows 70 % CR in transplant‑ineligible patients, while dual‑targeting KITE‑753/363 and Arcellx’s iMMagine‑1 deliver 83–78 % ORR and durable remissi…

Gilead’s launch of lenacapavir in sub‑Saharan Africa signals a major HIV prevention breakthrough and a strong investment play as options surge and market access expands.

Gilead’s ARTISTRY‑1 Phase 3 trial shows single‑tablet bictegravir/lenacapavir matches multi‑tablet regimens for virologic suppression, with similar safety and lower pill burden, boosting adherence and cost savings for HIV patients.

Gilead Sciences Inc. is set to report its Q4 2024 earnings on October 30, with analysts expecting a modest EPS gain and revenue decline, amidst a competitive landscape and regulatory headwinds.

Gilead Sciences’ Phase III ASCENT-03 trial has shown that its cancer treatment Trodelvy significantly improves outcomes for patients with metastatic triple-negative breast cancer, meeting its primary endpoint and paving the way for potential FDA app…

Gilead Sciences’ stock price declined 1% after CVS excluded its new HIV medication Yeztugo from its formulary, but the company has since made a bold move to expand its oncology pipeline through a $350 million acquisition.

Gilead Sciences exceeded expectations in its strong second quarter, driven by the success of its HIV medication Biktarvy, and has revised its 2025 guidance upwards.

The biotech sector is experiencing a surge in optimism, with Gilead Sciences and other key players seeing significant gains in stock price due to expectations of a US interest rate cut.

Gilead Sciences’ stock price surged 2.9% after the European Medicines Agency recommended its HIV prevention treatment lenacapavir for approval in the EU.